Rasche T, Emmert D, Stieber C, Mücke M, Conrad R
Zentrum für Seltene Erkrankungen (ZSEB), Universitätsklinikum Bonn, Bonn, Deutschland.
Institut für Hausarztmedizin, Universitätsklinikum Bonn, Bonn, Deutschland.
Urologe A. 2018 May;57(5):558-562. doi: 10.1007/s00120-018-0636-0.
In recent years, the media and scientists have shown increased interest in cannabis-based drugs.
Background information about cannabis-based drugs and their mechanism of action as well as discussion of possible applications as supportive therapy or in palliative medicine, respectively, are presented.
The recent literature was examined and evaluated.
In many medical fields, we do not have sufficient evidence for the efficacy of cannabinoids. In German pharmaceutical legislation, the use of nabiximols for the treatment of intermediate to severe, therapy-resistant spasticity in multiple sclerosis is the only approved indication for cannabis-based drugs. Furthermore, in view of the current evidence cannabinoids, combined with established treatments and as part of an individual therapeutic attempt, can be used for neuropathic pain, cancer-associated pain and human immunodeficiency virus (HIV)-related cachexia.
In most cases, today's assessment of cannabinoids relies on studies that are classified as low evidence. Therefore, further studies which involve more participants and evaluate long-term effects are needed.
近年来，媒体和科学家对大麻类药物表现出越来越浓厚的兴趣。
介绍大麻类药物的背景信息及其作用机制，并分别讨论其作为支持性治疗或姑息医学中可能应用的情况。
对近期文献进行审查和评估。
在许多医学领域，我们没有足够的证据证明大麻素的疗效。在德国药品立法中，使用纳布西莫尔治疗多发性硬化症中至重度、治疗抵抗性痉挛是大麻类药物唯一获批的适应症。此外，鉴于目前的证据，大麻素与既定治疗方法相结合，并作为个体化治疗尝试的一部分，可用于治疗神经性疼痛、癌症相关疼痛和人类免疫缺陷病毒（HIV）相关恶病质。
在大多数情况下，当今对大麻素的评估依赖于被归类为低证据的研究。因此，需要进行更多涉及更多参与者并评估长期效果的进一步研究。
